Conference Coverage

Antimalarials prove protective against long-term lupus damage

Publish date: November 18, 2013

 

AT THE ACR ANNUAL MEETING

Power calculations based upon the SLICC Inception Cohort Study suggest such trials could be relatively modest in size, he added.

SLICC receives financial support from GlaxoSmithKline, Bristol-Myers Squibb, and Human Genome Sciences. Dr. Bruce reported receiving research funding from GlaxoSmithKline, Bristol-Myers Squibb, Roche, and UCB.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Biologic therapy doesn’t preclude vaccinating psoriasis patients
MDedge Dermatology
Apremilast promising for Behçet’s syndrome
MDedge Dermatology
Treatment adherence poor among Medicaid beneficiaries with lupus
MDedge Dermatology
Systemic sclerosis brings sharply increased MI risk
MDedge Dermatology
Treat-to-target approach for psoriatic arthritis found beneficial
MDedge Dermatology
Novel predictor of poor outcomes in lupus pregnancies
MDedge Dermatology
Abatacept may reduce maintenance immunosuppression need in lupus nephritis
MDedge Dermatology
Cyclophosphamide and rituximab combo reduced severe lupus flares
MDedge Dermatology
Apremilast’s positive study results made it the talk of ACR 2013
MDedge Dermatology
Depression accounts for psoriatics’ increased MI risk
MDedge Dermatology